DOCICAR: Cardiac Dysfunction in Cirrhosis

This study has been completed.
Sponsor:
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00250315
First received: November 4, 2005
Last updated: October 31, 2007
Last verified: October 2007
  Purpose

Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.


Condition Intervention Phase
Cirrhosis
Cirrhotic Cardiomyopathy
Drug: Dobutamine
Phase 3

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.

Resource links provided by NLM:


Further study details as provided by Hvidovre University Hospital:

Study Start Date: November 2005
Study Completion Date: October 2007
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non alkoholic cirrhosis

Exclusion Criteria:

  • Coma hepaticum
  • Primary cardiac diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00250315

Locations
Denmark
Hvidovre University Hospital
Copenhagen, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Investigators
Study Director: Søren Møller, DrMsci, MD Hvidovre University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00250315     History of Changes
Other Study ID Numbers: (KF) 01 270675
Study First Received: November 4, 2005
Last Updated: October 31, 2007
Health Authority: Denmark: Sundhedsstyrelsen

Additional relevant MeSH terms:
Liver Cirrhosis
Fibrosis
Cardiomyopathies
Liver Diseases
Digestive System Diseases
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Dobutamine
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on September 14, 2014